

Diese Webseite verwendet Cookies

Wir verwenden Cookies, um die Nutzung unserer Webseiten zu erleichtern, die Nutzung unserer Webseiten zu verstehen und Werbemaßnahmen zu optimieren. Alternativ können Sie nur notwendige Cookies verwenden. In unserer [Cookie-Richtlinie](#) erfahren Sie mehr und können Ihre Einstellungen ändern.

Akzeptieren

Details zeigen

Nachricht vom 19.11.2020 | 07:00

Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous
19.11.2020 / 07:00

The issuer is solely responsible for the content of this announcement.

Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020

HALLE (SAALE) / Munich, Germany, 19 November 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), a biotechnology company focused on developing first-in-class therapeutics targeting post-translational modifying enzymes, announced today that it will publish its third quarter business update for the period ended September 30, 2020 on Thursday, November 26, 2020, in the form of an interim management report.

###

For more information, please contact:

Vivoryon Therapeutics AG

Dr. Ulrich Dauer, CEO

Email: contact@vivoryon.com

Trophic Communications

Gretchen Schweitzer / Joanne Tudorica

Tel: +49 172 861 8540 / +49 176 2103 7191

Email: vivoryon@trophic.eu

About Vivoryon Therapeutics AG

With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.
www.vivoryon.com

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Diese Webseite verwendet Cookies

Wir verwenden Cookies, um die Nutzung unserer Webseiten zu erleichtern, die Nutzung unserer Webseiten zu verstehen und Werbemaßnahmen zu optimieren. Alternativ können Sie nur notwendige Cookies verwenden. In unserer [Cookie-Richtlinie](#) erfahren Sie mehr und können Ihre Einstellungen ändern.

[Akzeptieren](#)[Details zeigen](#)

06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: contact@vivoryon.com
Internet: www.vivoryon.com
ISIN: DE0007921835
WKN: 792183
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1149141

End of News

DGAP News Service

DGAP – ein Service der EQS Group AG

[Twitter](#) | [Impressum](#) | [AGB](#) | [Datenschutzhinweise](#) | [Cookie-Richtlinie](#)